[
    {
     "kind": "calendar#event",
     "etag": "\"3290385624590000\"",
     "id": "e6c4e9doneuvuoeaqu3dfs4v7o",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ZTZjNGU5ZG9uZXV2dW9lYXF1M2RmczR2N28gZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
     "created": "2022-02-18T14:00:12.000Z",
     "updated": "2022-02-18T14:00:12.295Z",
     "summary": "AMLX Amylyx Pharmaceuticals, Inc. FDA AdCom",
     "description": "2022-03-30 The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals, Inc., for the treatment of amyotrophic lateral sclerosis (ALS). https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/march-30-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
      "displayName": "Adcom",
      "self": true
     },
     "start": {
      "date": "2022-03-30"
     },
     "end": {
      "date": "2022-03-30"
     },
     "iCalUID": "e6c4e9doneuvuoeaqu3dfs4v7o@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
        "kind": "calendar#event",
        "etag": "\"3245277611346000\"",
        "id": "fsftu5k7hrqdd6a4hgm44eurp8",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=ZnNmdHU1azdocnFkZDZhNGhnbTQ0ZXVycDggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-06-02T13:00:05.000Z",
        "updated": "2021-06-02T13:00:05.673Z",
        "summary": "AKBA Akebia Therapeutics, Inc. PDUFA",
        "description": "2022-03-29 The FDA assigned the application standard review and a Prescription Drug User Fee Act target action date of March 29, 2022. https://www.sec.gov/Archives/edgar/data/0001517022/000119312521177692/d190142d8k.htm",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-03-29"
        },
        "end": {
         "date": "2022-03-29"
        },
        "iCalUID": "fsftu5k7hrqdd6a4hgm44eurp8@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3250980010878000\"",
        "id": "egbmicho8ufrjplsp71rvd1vks",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=ZWdibWljaG84dWZyanBsc3A3MXJ2ZDF2a3MgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-07-05T13:00:05.000Z",
        "updated": "2021-07-05T13:00:05.439Z",
        "summary": "HCM HUTCHMED PDUFA",
        "description": "2022-04-30 U.S. FDA has assigned a target action date of April 30, 2022 https://www.sec.gov/Archives/edgar/data/0001648257/000164825721000048/hcm-20210702ex9912e239f.htm",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-30"
        },
        "end": {
         "date": "2022-04-30"
        },
        "iCalUID": "egbmicho8ufrjplsp71rvd1vks@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3257373617528000\"",
        "id": "9m0v7qh7jujqbavrir8le2ppmo",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=OW0wdjdxaDdqdWpxYmF2cmlyOGxlMnBwbW8gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-08-11T13:00:08.000Z",
        "updated": "2021-08-11T13:00:08.764Z",
        "summary": "MRK MERCK & CO., INC. PDUFA",
        "description": "2022-03-28 The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of March 28, 2022. http://www.businesswire.com/news/home/20210810005544/en/FDA-Accepts-Application-for-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-as-Single-Agent-for-Certain-Patients-With-MSI-HdMMR-Advanced-Endometrial-Carcinoma",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-03-28"
        },
        "end": {
         "date": "2022-03-28"
        },
        "iCalUID": "9m0v7qh7jujqbavrir8le2ppmo@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3261372925976000\"",
        "id": "dkinb5e2oomj2g0m15nogi8imk",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=ZGtpbmI1ZTJvb21qMmcwbTE1bm9naThpbWsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-09-03T16:27:42.000Z",
        "updated": "2021-09-03T16:27:42.988Z",
        "summary": "SUPN Supernus Pharmaceuticals, Inc. PDUFA",
        "description": "2022-04-29 The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022. https://www.globenewswire.com/news-release/2021/09/02/2291229/19871/en/Supernus-Announces-Qelbree-sNDA-for-Adult-Indication-Accepted-for-Review-by-FDA.html",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-29"
        },
        "end": {
         "date": "2022-04-29"
        },
        "iCalUID": "dkinb5e2oomj2g0m15nogi8imk@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3263421631224000\"",
        "id": "jma0cvda2e4o9suj0b9t38fld4",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=am1hMGN2ZGEyZTRvOXN1ajBiOXQzOGZsZDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-09-15T13:00:15.000Z",
        "updated": "2021-09-15T13:00:15.612Z",
        "summary": "AXSM Axsome Therapeutics, Inc. PDUFA",
        "description": "2022-04-30 NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Companys New Drug Application (NDA) for AXS-07 for the acute treatment of migraine, and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2022 for the NDA. https://www.globenewswire.com/news-release/2021/09/14/2296511/33090/en/Axsome-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-for-AXS-07-for-the-Acute-Treatment-of-Migraine.html",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-30"
        },
        "end": {
         "date": "2022-04-30"
        },
        "iCalUID": "jma0cvda2e4o9suj0b9t38fld4@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3271024805536000\"",
        "id": "n2hmt7m8attc1ib0iu0m6vhfj8",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=bjJobXQ3bThhdHRjMWliMGl1MG02dmhmajggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-10-29T13:00:02.000Z",
        "updated": "2021-10-29T13:00:02.768Z",
        "summary": "MRK MERCK & CO., INC. PDUFA",
        "description": "2022-04-21 Additionally, the FDA has accepted for review two supplemental New Drug Applications for ZERBAXA in pediatric complicated urinary tract infections and complicated intra-abdominal infections with PDUFA dates of April 21, 2022, and May 2, 2022, respectively. http://www.businesswire.com/news/home/20211028005322/en/Merck-Announces-Third-Quarter-2021-Financial-Results",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-21"
        },
        "end": {
         "date": "2022-04-21"
        },
        "iCalUID": "n2hmt7m8attc1ib0iu0m6vhfj8@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3271716026716000\"",
        "id": "b7t3h92vff3db3cs59irq8csnk",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=Yjd0M2g5MnZmZjNkYjNjczU5aXJxOGNzbmsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-11-02T13:00:13.000Z",
        "updated": "2021-11-02T13:00:13.358Z",
        "summary": "INCY INCYTE PDUFA",
        "description": "2022-04-30 This designation shortens the review period by four months as compared to Standard Review so the Prescription Drug User Fee Act (PDUFA) target action date for these indications is April 30, 2022. http://www.businesswire.com/news/home/20211101005269/en/Incyte-Announces-Acceptance-of-NDA-for-Parsaclisib-for-Three-Types-of-Relapsed-or-Refractory-Non-Hodgkin-Lymphomas",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-30"
        },
        "end": {
         "date": "2022-04-30"
        },
        "iCalUID": "b7t3h92vff3db3cs59irq8csnk@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3276907226340000\"",
        "id": "6l7kc4qri37dtdcprnkcl6snpo",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=Nmw3a2M0cXJpMzdkdGRjcHJua2NsNnNucG8gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-12-02T14:00:13.000Z",
        "updated": "2021-12-02T14:00:13.170Z",
        "summary": "BTAI BioXcel Therapeutics PDUFA",
        "description": "2022-04-05 PDUFA date extended by three months to April 5, 2022 https://www.globenewswire.com/news-release/2021/12/01/2343926/0/en/BioXcel-Therapeutics-Announces-Extension-of-FDA-Review-Period-of-its-NDA-for-BXCL501-for-the-Acute-Treatment-of-Agitation-Associated-with-Schizophrenia-and-Bipolar-Disorders.html",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-05"
        },
        "end": {
         "date": "2022-04-05"
        },
        "iCalUID": "6l7kc4qri37dtdcprnkcl6snpo@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3278808015786000\"",
        "id": "3nb2ppe9s3fqvm0495qm0mbn44",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=M25iMnBwZTlzM2Zxdm0wNDk1cW0wbWJuNDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-12-13T14:00:07.000Z",
        "updated": "2021-12-13T14:00:07.893Z",
        "summary": "GILD GILEAD SCIENCES, INC. PDUFA",
        "description": "2022-04-01 The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review designation to Yescarta for this patient population with a target action date under the Prescription Drug User Fee Act (PDUFA) of April 1, 2022. http://www.businesswire.com/news/home/20211211005047/en/Yescarta%C2%AE-CAR-T-Cell-Therapy-Quadruples-Median-Event-Free-Survival-Duration-Over-Standard-of-Care-in-Second-Line-Relapsed-or-Refractory-Large-B-Cell-Lymphoma",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-01"
        },
        "end": {
         "date": "2022-04-01"
        },
        "iCalUID": "3nb2ppe9s3fqvm0495qm0mbn44@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3278808030754000\"",
        "id": "dt1vg8kh3gurg9pnegtfljvg44",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=ZHQxdmc4a2gzZ3VyZzlwbmVndGZsanZnNDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2021-12-13T14:00:15.000Z",
        "updated": "2021-12-13T14:00:15.377Z",
        "summary": "LIAN LianBio PDUFA",
        "description": "2022-04-28 LianBios partner BMS has announced a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2022 for the Companys New Drug Application to the U.S. Food and Drug Administration (FDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). https://www.sec.gov/Archives/edgar/data/0001831283/000119312521352750/d455505dex991.htm",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-28"
        },
        "end": {
         "date": "2022-04-28"
        },
        "iCalUID": "dt1vg8kh3gurg9pnegtfljvg44@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3287966413096000\"",
        "id": "d046t5rnjifmv6clh313urnarc",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=ZDA0NnQ1cm5qaWZtdjZjbGgzMTN1cm5hcmMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2022-02-04T14:00:06.000Z",
        "updated": "2022-02-04T14:00:06.548Z",
        "summary": "ATRS Antares Pharma, Inc. PDUFA",
        "description": "2022-03-28 The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act (PDUFA). https://www.globenewswire.com/news-release/2022/02/03/2378482/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-NDA-Resubmission-for-TLANDO.html",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-03-28"
        },
        "end": {
         "date": "2022-03-28"
        },
        "iCalUID": "d046t5rnjifmv6clh313urnarc@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3287966431646000\"",
        "id": "6s3lo3fpdna6p8h658nt0bvep4",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=NnMzbG8zZnBkbmE2cDhoNjU4bnQwYnZlcDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2022-02-04T14:00:15.000Z",
        "updated": "2022-02-04T14:00:15.823Z",
        "summary": "LPCN Lipocine Inc. PDUFA",
        "description": "2022-03-28 The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act (PDUFA). https://www.sec.gov/Archives/edgar/data/0001535955/000149315222003057/ex99-1.htm",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-03-28"
        },
        "end": {
         "date": "2022-03-28"
        },
        "iCalUID": "6s3lo3fpdna6p8h658nt0bvep4@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3290385606986000\"",
        "id": "knsedk3iml9jaatbbt0n8htc7g",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=a25zZWRrM2ltbDlqYWF0YmJ0MG44aHRjN2cgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2022-02-18T14:00:03.000Z",
        "updated": "2022-02-18T14:00:03.493Z",
        "summary": "CHRS Coherus BioSciences, Inc. PDUFA",
        "description": "2022-04-30 U.S. Food and Drug Administration (FDA) granted toripalimab BLA priority review for nasopharyngeal carcinoma (NPC) and assigned a target action date of April 30, 2022. https://www.globenewswire.com/news-release/2022/02/17/2387556/33333/en/Coherus-BioSciences-Reports-Fourth-Quarter-and-Full-Year-2021-Results.html",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-30"
        },
        "end": {
         "date": "2022-04-30"
        },
        "iCalUID": "knsedk3iml9jaatbbt0n8htc7g@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3291076808350000\"",
        "id": "lcjaqjpu6858ole17i85s9ooqo",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=bGNqYXFqcHU2ODU4b2xlMTdpODVzOW9vcW8gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
        "created": "2022-02-22T14:00:04.000Z",
        "updated": "2022-02-22T14:00:04.175Z",
        "summary": "BMY BRISTOL MYERS SQUIBB PDUFA",
        "description": "2022-04-28 Based on data from the EXPLORER-HCM study, the company has a PDUFA date in the U.S. of April 28, 2022. http://www.businesswire.com/news/home/20220215005925/en/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-VALOR-HCM-Trial-Evaluating-Mavacamten-in-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy-Who-are-Eligible-for-Septal-Reduction-Therapy",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
         "displayName": "PDUFA",
         "self": true
        },
        "start": {
         "date": "2022-04-28"
        },
        "end": {
         "date": "2022-04-28"
        },
        "iCalUID": "lcjaqjpu6858ole17i85s9ooqo@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       }
   ]